OncoPharm
John Bossaer
Add to My Podcasts
Episodes
About
Reviews
Promote
Mirvetuximab Soravtansine
19 minutes
Posted Nov 17, 2022 at 4:47 pm.
0:00
19:29
Add to My Queue
Download
MP3
Share
episode
Share at current time
Show notes
A new antibody-drug conjugate is approved for ovarian cancer.
Previous
Metastatic NSCLC Updates: Role of CTLA-4 inhibitors?
Next
Bad News For Belantamab-Mafodotin And Atezolizumab's Bladder Cancer Indication
← See all 273 episodes of OncoPharm